RMDA Income Statement - TTM - Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E)

Income Statement (TTM)

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000,000 except per share units.

	2020 09-30	2020 12-31	2021 03-31	2021 06-30	2021 09-30	2021 12-31	2022 03-31	2022 06-30	2022 09-30	2022 12-31	2023 03-31	2023 06-30	2023 09-30	2023 12-31	2024 03-31	2024 06-30	2024 09-30	2024 12-31	2025 03-31	2025 06-30
Revenue	947	960	1,010	1,060	1,140	1,246	1,321	1,420	1,487	1,484	1,533	1,615	1,779	1,922	1,987	2,101	2,319	2,769	3,178	3,576
Change (%)		1.35	5.22	4.96	7.48	9.36	5.95	7.54	4.71	-0.20	3.30	5.35	10.17	8.05	3.34	5.76	10.35	19.41	14.79	12.54
% of Revenue	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00

Cost Of Sales	489	514	545	575	622	670	693	743	761	765	809	854	948	1,018	1,064	1,116	1,251	1,487	1,692	1,891
Change (%)		5.24	5.94	5.61	8.02	7.72	3.46	7.22	2.44	0.57	5.67	5.65	10.98	7.40	4.46	4.88	12.15	18.86	13.75	11.78
% of Revenue	51.59	53.57	53.93	54.27	54.54	53.72	52.46	52.30	51.17	51.57	52.75	52.90	53.29	52.97	53.54	53.10	53.96	53.72	53.23	52.87

Gross Operating Profit	459	446	465	485	518	577	628	677	726	719	724	761	831	904	923	985	1,067	1,281	1,486	1,686
Change (%)		-2.79	4.39	4.21	6.83	11.32	8.85	7.89	7.19	-1.02	0.77	5.01	9.26	8.80	2.09	6.78	8.31	20.06	15.98	13.40
% of Revenue	48.41	46.43	46.07	45.73	45.46	46.28	47.54	47.70	48.83	48.43	47.25	47.10	46.71	47.03	46.46	46.90	46.04	46.28	46.77	47.13

SG&A	253	260	267	273	283	303	310	334	349	382	397	413	443	466	489	517	533	586	636	709
Change (%)		2.87	2.60	2.53	3.30	7.35	2.35	7.69	4.38	9.61	3.79	4.07	7.21	5.13	5.02	5.69	3.06	9.98	8.59	11.47
% of Revenue	26.68	27.08	26.40	25.79	24.79	24.33	23.51	23.54	23.46	25.77	25.90	25.58	24.90	24.22	24.62	24.60	22.97	21.16	20.02	19.83

R&D
Change (%)
% of Revenue

OpEx	740	773	811	848	903	972	1,002	1,072	1,104	1,142	1,199	1,265	1,388	1,477	1,544	1,624	1,774	2,046	2,300	2,571
Change (%)		4.50	4.83	4.61	6.55	7.61	3.11	6.91	3.04	3.39	5.04	5.51	9.73	6.35	4.58	5.14	9.27	15.30	12.43	11.77
% of Revenue	78.10	80.52	80.22	79.95	79.26	77.99	75.90	75.46	74.26	76.94	78.23	78.35	78.04	76.81	77.73	77.28	76.52	73.89	72.37	71.88

Operating Income	208	187	200	213	236	274	318	348	383	342	334	350	391	446	442	477	544	723	878	1,006
Change (%)		-9.88	6.85	6.41	11.17	16.04	16.03	9.50	9.82	-10.57	-2.50	4.78	11.74	14.09	-0.77	7.93	14.02	32.81	21.46	14.55
% of Revenue	21.90	19.48	19.78	20.05	20.74	22.01	24.10	24.54	25.74	23.06	21.77	21.65	21.96	23.19	22.27	22.72	23.48	26.11	27.63	28.12

Interest Expense	-102	-97	-94	-92	-92	-91	-89	-87	-87	-89	-98	-122	-156	-191	-222	-253	-261	-307	-377	-434
Change (%)		-5.10	-2.29	-2.34	-0.66	-0.64	-2.05	-2.85	0.82	2.00	10.41	24.19	28.03	22.28	15.94	14.16	3.31	17.51	22.70	15.17
% of Revenue	-10.75	-10.07	-9.35	-8.70	-8.04	-7.30	-6.75	-6.10	-5.87	-6.00	-6.42	-7.56	-8.79	-9.95	-11.16	-12.04	-11.28	-11.10	-11.86	-12.14

Net Income	119	112	121	130	151	181	222	244	269	246	240	237	243	245	235	248	287	387	413	439
Change (%)		-6.08	8.02	7.43	15.68	20.25	22.59	9.69	10.42	-8.64	-2.15	-1.35	2.36	0.87	-3.88	5.39	15.88	34.77	6.51	6.45
% of Revenue	12.61	11.68	11.99	12.28	13.21	14.53	16.81	17.15	18.08	16.56	15.68	14.69	13.64	12.74	11.85	11.80	12.40	13.99	12.98	12.28

Source: Capital IQ

Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) (S.A.E) - Income Statement (TTM)

Income Statement (TTM)